Speratum Biopharma, Inc. (“Speratum”) is an innovative biotechnology company focused on research and development of targeted nucleic acid delivery systems and oligonucleotide therapeutics. Speratum’s Nano-inTM and No-Pass MimicTM technologies have broad applicability as platform technologies for nucleic acid drug delivery and oligonucleotide administration in vitro and in vivo, and have been out-licensed for multiple therapeutic modalities, including skin diseases therapeutics and antiviral treatments.

Speratum is currently in final pre-clinical stages of development for its first therapeutic, a small RNA tumor suppressor against pancreatic, ovarian, and other cancers.

The company was founded in 2014 with technologies licensed from Baylor College of Medicine. Since then, Speratum has continued to innovate with with best-in class, proprietary technologies to generate a ground-breaking oligonucleotide, nucleic acid, and cell therapy platform.

For more information about Speratum Biopharma, please e-mail info@speratum.com